marketcap
Facebook
Twitter
Telegram
Report an ErrorQuarterly report 2024-Q2
added 08-12-2024
Agile Therapeutics Balance Sheet 2011-2024 | AGRX
Annual Balance Sheet Agile Therapeutics
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-676 K | -3.5 M | -2.14 M | 2.09 M | -34.3 M | -7.85 M | -25.3 M | -32.7 M | -18.9 M | -25.4 M | 12.8 M | -5.23 M | - |
Long Term Debt |
1.52 M | 1.43 M | 16.8 M | 16.4 M | - | - | - | 10.9 M | 13 M | 9.83 M | 9.77 M | 14.8 M | - |
Long Term Debt Current |
366 K | 319 K | 175 K | 138 K | 172 K | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | 16.4 M | - | - | - | 10.9 M | 13 M | 9.83 M | 79 M | 84 M | - |
Total Current Liabilities |
20.8 M | 13.4 M | 29.3 M | 7.35 M | 3.8 M | 2.22 M | 14.3 M | 10.7 M | 7.93 M | 8.99 M | - | - | - |
Total Liabilities |
26.6 M | 19.8 M | 30.1 M | 23.7 M | 3.8 M | 2.22 M | 14.3 M | 21.6 M | 21 M | 18.8 M | 85.8 M | 86.1 M | - |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-423 M | -409 M | -387 M | -312 M | -260 M | -242 M | -222 M | -193 M | -165 M | -134 M | -118 M | -104 M | - |
Total Assets |
10.3 M | 14.2 M | 39.3 M | 73.1 M | 49.5 M | 22.4 M | 50.6 M | 63.9 M | 50.7 M | 54.8 M | 14.4 M | 27.5 M | - |
Cash and Cash Equivalents |
2.56 M | 5.25 M | 19.1 M | 14.5 M | 34.5 M | 7.85 M | 36 M | 48.8 M | 34.4 M | 40.2 M | 2.12 M | 20 M | - |
Book Value |
-16.3 M | -5.54 M | 9.27 M | 49.3 M | 45.7 M | 20.2 M | 36.3 M | 42.3 M | 29.7 M | 36 M | -71.4 M | -58.6 M | - |
Total Shareholders Equity |
-16.3 M | -5.54 M | 3.92 M | 49.3 M | 45.7 M | 20.2 M | 36.3 M | 42.3 M | 29.7 M | 36 M | -71.4 M | -58.6 M | - |
All numbers in USD currency
Quarterly Balance Sheet Agile Therapeutics
| 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
- | - | 1.52 M | 1.59 M | 1.56 M | 1.51 M | 1.43 M | 1.32 M | 12.6 M | 12.3 M | 16.8 M | 16.4 M | 16 M | 15.6 M | 16.4 M | 16.4 M | 16.4 M | 16.4 M | - | 34 K | 82 K | 128 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
36.9 M | 22.9 M | 26.6 M | 23.3 M | 24.7 M | 23.1 M | 19.8 M | 12.2 M | 29.4 M | 26.6 M | 30.1 M | 26 M | 27.7 M | 24.4 M | 23.7 M | 23.7 M | 23.7 M | 23.7 M | 3.8 M | 3.8 M | 3.8 M | 3.8 M | 2.22 M | - | - | - | 14.3 M | - | - | - | 21.6 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-434 M | -422 M | -423 M | -419 M | -418 M | -414 M | -409 M | -431 M | -411 M | -399 M | -387 M | -364 M | -347 M | -329 M | -312 M | -312 M | -312 M | -312 M | -260 M | -260 M | -260 M | -260 M | -242 M | -242 M | -242 M | -242 M | -222 M | -222 M | -222 M | -222 M | -193 M | -193 M | -193 M | -193 M | -165 M | -165 M | -165 M | -165 M | -134 M | -134 M | -134 M | -134 M | -118 M | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
15 M | 12.6 M | 10.3 M | 10.9 M | 12.6 M | 13.7 M | 14.2 M | 18.5 M | 32.8 M | 29.3 M | 39.3 M | 36.7 M | 52.3 M | 59.5 M | 73.1 M | 73.1 M | 73.1 M | 73.1 M | 49.5 M | 49.5 M | 49.5 M | 49.5 M | 22.4 M | 22.4 M | 22.4 M | 22.4 M | 50.6 M | 50.6 M | 50.6 M | 50.6 M | 63.9 M | 63.9 M | 63.9 M | 63.9 M | 50.4 M | 50.4 M | 50.4 M | 50.4 M | 54.8 M | 54.8 M | 54.8 M | 54.8 M | 14.4 M | 14.4 M | 14.4 M | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
2.85 M | 2.62 M | 2.56 M | 2.87 M | 2.78 M | 4.43 M | 5.25 M | 6.14 M | 13 M | 3.74 M | 19.1 M | 14.7 M | 26.1 M | 16.5 M | 14.5 M | 14.5 M | 14.5 M | 14.5 M | 34.5 M | 34.5 M | 34.5 M | 34.5 M | 7.85 M | 7.85 M | 7.85 M | 7.85 M | 36 M | 36 M | 36 M | 36 M | 48.8 M | 48.8 M | 48.8 M | 48.8 M | 34.4 M | 34.4 M | 34.4 M | 34.4 M | 40.2 M | 40.2 M | 40.2 M | 40.2 M | 2.12 M | 2.12 M | 2.12 M | - | 20 M | - | - | - | 9.56 M | - | - | - |
Book Value |
-21.9 M | -10.3 M | -16.3 M | -12.4 M | -12.1 M | -9.43 M | -5.54 M | 6.26 M | 3.42 M | 2.74 M | 9.27 M | 10.7 M | 24.6 M | 35.1 M | 49.3 M | 49.3 M | 49.3 M | 49.3 M | 45.7 M | 45.7 M | 45.7 M | 45.7 M | 20.2 M | 22.4 M | 22.4 M | 22.4 M | 36.3 M | 50.6 M | 50.6 M | 50.6 M | 42.3 M | 63.9 M | 63.9 M | 63.9 M | 50.4 M | 50.4 M | 50.4 M | 50.4 M | 54.8 M | 54.8 M | 54.8 M | 54.8 M | 14.4 M | 14.4 M | 14.4 M | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
-21.9 M | -10.3 M | -16.3 M | -12.4 M | -12.1 M | -9.43 M | -5.54 M | -3.02 M | 2.37 M | -5.36 M | 9.27 M | 10.7 M | 24.6 M | 35.1 M | 49.3 M | 49.3 M | 49.3 M | 49.3 M | 45.7 M | 45.7 M | 45.7 M | 45.7 M | 20.2 M | 20.2 M | 20.2 M | 20.2 M | 36.3 M | 36.3 M | 36.3 M | 36.3 M | 42.3 M | 42.3 M | 42.3 M | 42.3 M | 29.7 M | 29.7 M | 29.7 M | 29.7 M | 36 M | 36 M | 36 M | 36 M | -71.4 M | -71.4 M | -71.4 M | - | -58.6 M | - | - | - | -36 M | - | - | - |
All numbers in USD currency